MAPT and COVID-19: In addition, in convalescent patients, there appeared to be a second, separate, process, which was characterized by a different pattern of serum brain injury biomarkers (more specifically elevation of total tau), which was not related to initial COVID-19 severity or pro-inflammatory cytokine levels but was associated with the presence of IgM autoantibodies.